Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models

• Published in: PloS one Vol. 12; no. 10; p. e0186137
• Main Authors: Alfaleh, Mohamed A, Howard, Christopher B, Sedliarou, Ilya, Jones, Martina L, Gudhka, Reema, Vanegas, Natasha, Weiss, Jocelyn, Suurbach, Julia H, de Bakker, Christopher J, Milne, Michael R, Rumballe, Bree A, MacDiarmid, Jennifer A, Brahmbhatt, Himanshu, Mahler, Stephen M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 23.10.2017; Public Library of Science (PLoS)
• Subjects: Analysis; Animal models; Animals; Antibodies; Anticancer properties; Apoptosis; Asbestos; Bacteria; Biocompatibility; Bioengineering; Biology and Life Sciences; Bispecific antibodies; Breast cancer; Cancer; Cancer therapies; Cell division; Cell growth; Cell Proliferation; Cell receptors; Cell surface; Chemotherapy; Clinical trials; Confocal microscopy; Councils; Cytometry; Cytotoxic agents; Cytotoxicity; Doxorubicin; Drug delivery systems; Drug dosages; Drug efficacy; Drug resistance; Drug therapy; Drugs; Flow cytometry; Genetic aspects; Health aspects; Humans; Hypoxia; Immunoglobulins; Immunohistochemistry; Internalization; Medical research; Medicine and Health Sciences; Mesothelioma; Mesothelioma - pathology; Mice; Microscopy; Nanotechnology; Physiological aspects; Receptors; Receptors, Cell Surface - metabolism; Research and Analysis Methods; Selectivity; Side effects; Toxicity; Training; Tumors; Xenograft Model Antitumor Assays; Xenografts; Australia; Queensland Australia

Human malignant mesothelioma is a chemoresistant tumour that develops from mesothelial cells, commonly associated with asbestos exposure. Malignant mesothelioma incidence rates in European countries are still rising and Australia has one of the highest burdens of malignant mesothelioma on a populati...